Tuesday, November 17, 2026 Vol. I · No. 5
Health · Via STAT

STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial

Image: STAT

Sellas' experimental blood cancer immunotherapy reduced the risk of death in clinical trial.

This is a brief. The reporting belongs to STAT — read the complete story, with full context and credits, at the source.

Read the full story at STAT ↗

statnews.com

More from the Health desk